Company Profile

Implantica is a MedTech group dedicated to bringing innovative advances in technology into the body. Medical implants previously seen as unachievable will seek to alleviate unmet medical needs.

RefluxStop™

The Company’s lead product RefluxStop™ is a passive CE-marked implant for prevention of gastroesophageal reflux. RefluxStop™ has a completely different design thesis than existing current surgical gastroesophageal reflux disease treatments and has achieved excellent results in its CE mark clinical investigation with 5-year follow-up, which has been submitted to FDA in a PMA application. The Company believes RefluxStop™ has the potential to spur a paradigm shift in anti-reflux surgery as supported by the clinical trial results. RefluxStop has been on the market since the autumn 2018.

Implantable eHealth Platform

Implantica plans to bring to the fast-expanding eHealth market its sensor implant e-InVivo™, which is being designed to collect data from inside the body and transfers the data to external devices, such as a watch or directly to the caregiver. e-InVivo™ is being designed to monitor a multitude of health parameters and provide diagnostic information as well as control treatment of Smart medical implants from inside the body. Implantica’s eHealth platform e-InVivo is subject to further development and approval process.

Wireless Energising Platform

Implantica’s wireless energizing platform, being developed for the next generation of “Smart Medical Implants”, is being designed to make previously inconceivable medical implants possible. This disruptive technology will be designed to power and recharge remote controlled implants wirelessly through intact skin. Implantica’s wireless energizing platform is subject to further development and approval process.

The Prioritized Products

Implantica is focusing on two treatment fields, Urology and Gastrointestinal surgery, with its prioritized products: AppetiteControl™, a new implant that aims to treat obesity by controlling appetite, UriControl^®, a remote controlled implant to treat urinary incontinence for both men and women, and UriRestore^®, a remote-controlled device enabling patients who cannot urinate, such as spinal cord injury and MS patients, to urinate on demand using the wireless platform. Implantica’s UriControl^®, UriRestore^® and AppetiteControl^TM are subject to further development and approval process.

Extensive Patent Portfolio

Implantica has a large product pipeline supported by an extensive patent portfolio of more than 1’000 patent cases and over 300 inventions covering many applications for the Company’s platform technologies.